ClinicalTrials.Veeva

Menu
C

Cardiovascular Research of Northwest Indiana, LLC | Munster, IN

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Empagliflozin
Bococizumab
Obicetrapib
MK-1242
Ezetimibe
Triglycerides
BI 690517
Aldosterone
MK-1242-035
Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 20 total trials

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fract...

Active, not recruiting
Chronic Heart Failure With Reduced Ejection Fraction
Drug: Vericiguat
Drug: Placebo
Locations recently updated

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling
Heart Failure
Drug: BI 690517
Drug: Empagliflozin

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo
Locations recently updated

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and...

Active, not recruiting
Dyslipidemias
Hypercholesterolemia
Other: Combination Therapy placebo
Drug: Monotherapy ezetimibe

Trial sponsors

ZOLL Medical logo
Amgen logo
Boehringer Ingelheim logo
N
Pfizer logo
Abbott logo
C
Ionis Pharmaceuticals logo
Kowa logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems